A vaccine response study measures whether T cells recognize something. Whether they can recognize it at all is decided by which HLA molecules the donor carries, because a T cell only sees a peptide when it is held in a specific presenting molecule. Run the experiment across donors of unknown genotype and a substantial part of the variance is structural rather than biological.
MHC restriction as an experimental constraint
T cells recognize a peptide and the molecule presenting it as one composite shape. A response raised against a peptide on one allele does not transfer to the same peptide on another. This is not a subtlety; it is the mechanism.
Which means an epitope is only an epitope with respect to a presenting allele. A peptide that provokes a strong response in one donor may provoke nothing in another simply because that donor cannot present it, and no amount of assay optimisation will change that.
What this does to study design
| Design choice | Without HLA typing | With HLA typing |
|---|---|---|
| Donor selection | Convenience sample | Deliberate allele coverage |
| Non-responders | Unexplained | Predicted, and informative |
| Epitope mapping | Restriction inferred afterwards, if at all | Restriction assigned directly |
| Population inference | Weak, coverage unknown | Grounded in known allele frequencies |
| Variance | Attributed to assay noise | Partitioned into genotype and biology |
The non-responder row is the one that changes a study most. Without genotype, a donor who fails to respond is a data point that weakens the result. With genotype, that donor may be confirming the restriction rather than contradicting the finding.
Related product
Leukopak formats. Single-donor starting material, fresh or cryopreserved, with full donor documentation.
Class I and class II answer different questions
Class I molecules present intracellular peptides to CD8+ T cells and are the relevant restriction for cytotoxic responses. Class II molecules present extracellular peptides to CD4+ T cells and are the relevant restriction for helper responses, which matter for antibody development.
A study measuring only CD8 responses and typing only class I is coherent. A study measuring both and typing one is not, and the gap tends to appear as unexplained variance in the half that was not typed. Nomenclature and method are covered in the HLA typing guide.
Building a donor panel with deliberate coverage
A panel assembled for allele coverage rather than availability supports much stronger claims. Common alleles give population relevance. Deliberately included less common alleles test whether a response is broadly restricted or narrowly so. And holding the panel constant across a program means later results remain comparable with earlier ones.
That last point depends on being able to return to the same donors, which is why recall matters here as much as it does in manufacturing. The argument is in recallable donors.
Prior exposure is a second hidden variable
Cytomegalovirus status substantially and durably reshapes the T cell compartment, and prior exposure to related antigens produces cross-reactive memory that can look like a primary response. Both are documented donor attributes rather than things to discover in the data, and both can be used as selection criteria where availability allows.
OrganaBio documents high-resolution NGS HLA genotyping across HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ and HLA-DP at donor program level, with cytomegalovirus and Epstein-Barr virus status among the documented selection attributes, subject to availability. Material includes cryopreserved PBMCs and isolated T cells from the same donors.
Frequently asked questions
Why does donor HLA type constrain vaccine response studies?
T cells recognize a peptide only when it is presented in a specific HLA molecule, and recognize the two together as one shape. A peptide that provokes a strong response in one donor may provoke none in another simply because that donor cannot present it.
What happens to non-responders in an untyped study?
They appear as data points weakening the result. With genotype known, a non-responder may be confirming the restriction rather than contradicting the finding, which changes the interpretation entirely.
Should I type class I, class II, or both?
Match the typing to the readout. Class I restriction governs CD8 cytotoxic responses and class II governs CD4 helper responses. A study measuring both while typing only one will show unexplained variance in the untyped half.
How should a donor panel be assembled for vaccine work?
For deliberate allele coverage rather than availability. Common alleles give population relevance and deliberately included less common alleles test whether a response is broadly or narrowly restricted.
Why does the same panel need to remain available over time?
Because holding donors constant keeps later results comparable with earlier ones. That depends on being able to return to the same donors, which requires a repeat-collection program rather than finite banked inventory.
How does cytomegalovirus status affect vaccine response studies?
Prior exposure substantially and durably reshapes the T cell compartment, and exposure to related antigens can produce cross-reactive memory that resembles a primary response. Both are documented donor attributes rather than findings to uncover in the data.
Can epitope prediction substitute for donor typing?
Prediction identifies candidate epitopes for given alleles but does not tell you which alleles your donors carry. Without typing, a predicted epitope tested in an unmatched donor produces a negative result that means nothing.
Talk to OrganaBio
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
